The Accelerating Cancer Cures Advisory Committee is comprised of senior oncology leaders in the collaborating companies. A valuable resource for Damon Runyon Clinical Investigators, committee members are available for discussions and advice about the process of translating discoveries into therapeutics.


Richard Gaynor, MD
President of Research and Development
Neon Therapeutics

Christopher A. Slapak, MD
Vice President, Early Phase Clinical Research
Distinguished Lilly Scholar
Eli Lilly and Co.

Jorge DiMartino, MD, PhD
Vice President, Translational Development
Celgene Corporation

Dietmar Berger, MD, PhD
Senior Vice President, Global Head of Clinical Development for Hematology/Oncology Product Development
Genentech, Inc.

Nancy Valente, MD
Vice President, Global Hematology Development
Genentech, Inc.

Eric Rubin, MD
Vice President & Therapeutic Area Head Oncology
Clinical Development
Merck & Co., Inc.

Glenn Dranoff, MD
Global Head of Exploratory Immuno-Oncology
Novartis Institutes for BioMedical Research

Jeffrey A. Engelman, MD, PhD
Vice President and Global Head of Oncology
Novartis Institutes for BioMedical Research

  • You can support our innovative researchers.